Anti-Human CD1a FITC 25 tests
- Known as:
- Antibody toHuman CD1a fluorecein 25 tests
- Catalog number:
- 11-0019-41
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Human CD1a FITC 25 tests
Related genes to: Anti-Human CD1a FITC 25 tests
- Gene:
- CD1A NIH gene
- Name:
- CD1a molecule
- Previous symbol:
- CD1
- Synonyms:
- -
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-11
- Date modifiied:
- 2017-07-07
Related products to: Anti-Human CD1a FITC 25 tests
Related articles to: Anti-Human CD1a FITC 25 tests
- Pulmonary crystal-storing histiocytosis (CSH) without an associated haematological malignancy, lymphoproliferative disorder, plasma cell disorder, or other identifiable underlying condition is exceptionally rare. Long-term radiological data from published cases remain limited, and this case, contextualised by a narrative review of the literature, may expand the recognised imaging spectrum of localised pulmonary CSH. We report the case of a 59-year-old man with incidental multiple pulmonary lesions identified on CT thorax imaging. The lesions demonstrated an unusual combination of cystic change, cavitation, and surrounding ground-glass opacities. His medical history was significant for bipolar disorder treated with lithium and a 50-pack-year smoking history. Interval imaging showed progression, prompting further investigation and ultimately right upper lobectomy. Histopathological analysis confirmed pulmonary CSH; lesional cells contained crystalloid material and showed CD68 and PAS positivity, with dual kappa and lambda expression on immunohistochemistry. Markers for other differential diagnoses, including Congo red, birefringence, Langerin, and CD1a were negative. Following diagnosis and resection, serial imaging demonstrated fluctuating yet slowly progressive pulmonary abnormalities. No lymphoproliferative or plasma cell disorder has emerged after more than seven years of post-diagnostic surveillance and more than ten years since the initial imaging abnormality. This case demonstrates that the radiological spectrum of localised pulmonary CSH may include cystic, cavitary and ground-glass abnormalities, with subsequent fluctuating yet slowly progressive post-resection evolution. Pulmonary CSH should be considered in the differential diagnosis of unexplained or atypical pulmonary nodules, particularly when histiocyte-rich pathology with intracytoplasmic crystalloid material is identified. Long-term multidisciplinary surveillance is warranted. - Source: PubMed
Publication date: 2026/07/31
Halim DzufarMcGrath ErinnAmpazis DimitriosKrawczyk JanuszShatwan RamadanO'Regan Anthony - Langerhans cell histiocytosis (LCH) is a rare clonal myeloid disorder with a broad clinical spectrum ranging from isolated lesions to multisystem disease. We report the case of a two-year-five-month-old boy who presented with a six-month history of treatment-refractory bilateral otorrhea, progressive mandibular swelling with premature tooth loss, seborrheic skin lesions, and weight loss. Further evaluation revealed severe polyuria-polydipsia suggestive of central diabetes insipidus. Imaging demonstrated multifocal craniofacial osteolytic lesions with hypothalamic-pituitary involvement. Histopathological examination of a mandibular biopsy, supported by positive CD1a, S100, and CD68 immunostaining, confirmed the diagnosis of LCH. The patient was classified as having multisystem LCH without risk-organ involvement and was treated according to the LCH-III protocol with vinblastine and prednisone, alongside desmopressin therapy. At one-year follow-up, he showed significant clinical and radiological improvement without evidence of disease progression. This case highlights the diagnostic challenges of multisystem LCH in young children and emphasizes the importance of considering LCH in patients presenting with persistent otologic symptoms, craniofacial bone lesions, premature tooth loss, and diabetes insipidus. - Source: PubMed
Publication date: 2026/07/12
El Hachmi IkramGhanam AyadAzizi ManalEl Magroud MohammedRkain Maria - We report a case of a 71-year-old female with acute myeloid leukemia (AML), treated with chemotherapy and hematopoietic stem cell transplant (HSCT), who developed a clonally related non-Langerhans cell histiocytosis (NLCH). She presented with pink papules on the mid-upper cutaneous lip and thighs 3 months following HSCT. Skin biopsies revealed a dermal proliferation of cells with eosinophilic cytoplasm. Immunohistochemistry (IHC) studies demonstrated positivity for CD68, CD163, BRAF, cyclin D1, and Factor XIIIa and negativity for CD1a, S100, MPO, and CD20. Next-generation sequencing (NGS) with a comprehensive myeloid panel revealed corresponding pathogenic mutations to her AML, including BCOR Q176fs*40, IDH1 R132C, and TP53 Y163N, and an additional BRAF V600E mutation. Additional mutations in DNMT3A and KMT2A associated with her AML were not identified. These findings supported the diagnosis of NLCH sharing a clonal origin with the patient's AML. Work up demonstrated isolated cutaneous involvement without AML relapse; therefore, the skin lesions were treated with shave excision, topical tacrolimus 0.1% ointment, and topical clobetasol 0.05% cream without further systemic treatment. The acquired BRAF V600E mutation illustrates the potential for divergent myeloid differentiation and likely explains the emergence of a clonal NLCH after successful AML treatment. Genetic analysis in NLCH can establish clonality with associated hematologic malignancies, uncover actionable mutations, and guide treatment. - Source: PubMed
Publication date: 2026/08/11
Shimshak SerenaJiang LiuyanSokumbi Olayemi - Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by the invasion of CD68 CD163 CD1a macrophages into organs. It is marked by a variety of symptoms and ranges from asymptomatic bone involvement to a life-threatening systemic illness. Bone involvement occurs in more than 90% of cases. Although treatment depends on lesion severity and bone localization is not fatal, such lesions may lead to severe pain and disability. Conducting a bone biopsy is important for an exact diagnosis; however, it occasionally results in pathological fractures. Herein, we report a case of a pathological fracture of the tibia following biopsy-proven bone ECD in a 78-year-old woman with a history of right knee pain. - Source: PubMed
Publication date: 2026/07/07
Iwai TadashiIeguchi MakotoTaga TomoyaTakamatsu KiyohitoTerai Hidetomi - Rosai-Dorfman disease (RDD) with central nervous system (CNS) involvement poses substantial diagnostic challenges due to its propensity to mimic meningiomas or inflammatory pathologies. We present a series of three RDD cases with CNS involvement to evaluate their clinical, radiological, and histopathological features. The series includes a 30-year-old female with pachymeningitis and spinal involvement; a 66-year-old male with a skull base lesion; and a 45-year-old male presenting with trigeminal neuralgia secondary to a cavernous sinus lesion. In all instances, definitive diagnosis was achieved following surgical intervention and histopathological analysis, revealing hallmark emperipolesis and a characteristic immunohistochemical profile (S100+, CD68+, and CD1a-). Management comprised neurosurgical resection for decompression and diagnosis, supplemented by adjuvant corticosteroids and chemotherapy where indicated. This series underscores that RDD is a critical differential diagnosis for atypical extra-axial CNS lesions. A multidisciplinary approach is essential for optimizing patient outcomes. - Source: PubMed
Publication date: 2026/07/09
Souza Ramalho Paulade Assis Lopes GabrielBaldasserini Guimarães AlexandreFernandes Junger CarolinaReis Casal YuriSilva Franco AndréTrindade Gomes da Silva ViniciusVellutini Eduardo